Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with systemic sclerosis.
Epistemonikos ID: 008bfd93c18aa83e896ab3d4f0e6c9e5909252ad
First added on: May 22, 2024